Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Epidarex Capital
Deal Size : $5.0 million
Deal Type : Financing
Details : The net proceeds will be used to advance Harness’ lead Huntington’s Disease (HD) programme targeting FAN1 nuclease and pursue target discovery and validation activities in other neurodegenerative disease pathways.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Epidarex Capital
Deal Size : $5.0 million
Deal Type : Financing
Reset All
